Literature DB >> 33807662

Dispirooxindoles Based on 2-Selenoxo-Imidazolidin-4-Ones: Synthesis, Cytotoxicity and ROS Generation Ability.

Vladimir K Novotortsev1, Maxim E Kukushkin1,2, Viktor A Tafeenko1, Dmitry A Skvortsov1, Marina A Kalinina3, Roman V Timoshenko2, Nelly S Chmelyuk2, Liliya A Vasilyeva4, Boris N Tarasevich1, Petr V Gorelkin2, Alexander S Erofeev1,2, Alexander G Majouga1,2,5, Nikolai V Zyk1, Elena K Beloglazkina1.   

Abstract

A regio- and diastereoselective synthesis of two types of dispiro derivatives of 2-selenoxoimidazolidin-4-ones, differing in the position of the nitrogen atom in the central pyrrolidine ring of the spiro-fused system-namely, 2-selenoxodispiro[imidazolidine-4,3'-pyrrolidine-2',3″-indoline]-2″,5-diones (5a-h) and 2-senenoxodispiro[imidazolidine-4,3'-pyrrolidine-4',3″-indoline]-2″,5-diones (6a-m)-were developed based on a 1,3-dipolar cycloaddition of azomethine ylides generated from isatin and sarcosine or formaldehyde and sarcosine to 5-arylidene or 5-indolidene-2-selenoxo-tetrahydro-4H-imidazole-4-ones. Selenium-containing dispiro indolinones generally exhibit cytotoxic activity near to the activity of the corresponding oxygen and sulfur-containing derivatives. Compounds 5b, 5c, and 5e demonstrated considerable in vitro cytotoxicity in the 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium bromide (MTT) test (concentration of compounds that caused 50% death of cells (CC50) 7.6-8.7 μM) against the A549 cancer cell line with the VA13/A549 selectivity index 5.2-6.9; some compounds (5 and 6) increased the level of intracellular reactive oxygen species (ROS) in the experiment on A549 and PC3 cells using platinized carbon nanoelectrode. The tests for p53 activation for compounds 5 and 6 on the transcriptional reporter suggest that the investigated compounds can only have an indirect p53-dependent mechanism of action. For the compounds 5b, 6b, and 6l, the ROS generation may be one of the significant mechanisms of their cytotoxic action.

Entities:  

Keywords:  ROS generation; azomethine ylides; cytotoxicity; indolinones; prooxidant properties; selenohydantoins; spiro compounds

Mesh:

Substances:

Year:  2021        PMID: 33807662      PMCID: PMC7961907          DOI: 10.3390/ijms22052613

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  38 in total

1.  Discovery of Novel Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2-p53 Interaction.

Authors:  Andreas Gollner; Dorothea Rudolph; Heribert Arnhof; Markus Bauer; Sophia M Blake; Guido Boehmelt; Xiao-Ling Cockroft; Georg Dahmann; Peter Ettmayer; Thomas Gerstberger; Jale Karolyi-Oezguer; Dirk Kessler; Christiane Kofink; Juergen Ramharter; Jörg Rinnenthal; Alexander Savchenko; Renate Schnitzer; Harald Weinstabl; Ulrike Weyer-Czernilofsky; Tobias Wunberg; Darryl B McConnell
Journal:  J Med Chem       Date:  2016-11-15       Impact factor: 7.446

2.  Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy.

Authors:  Lei Wang; Jia-Ning Fu; Jing-Yu Wang; Cun-Jing Jin; Xiao-Yuan Ren; Qiang Tan; Jing Li; Han-Wei Yin; Kun Xiong; Tian-Yu Wang; Xin-Min Liu; Hui-Hui Zeng
Journal:  Anticancer Drugs       Date:  2011-09       Impact factor: 2.248

3.  Dantrolene, a direct acting skeletal muscle relaxant.

Authors:  K O Ellis; A W Castellion; L J Honkomp; F L Wessels; J E Carpenter; R P Halliday
Journal:  J Pharm Sci       Date:  1973-06       Impact factor: 3.534

4.  Organocatalytic Enantioselective Michael Addition between 3-(3-hydroxy-1H-pyrazol-1-yl)Oxindole and β-Nitrostyrene for the Preparation of Chiral Di-substituted Oxindoles.

Authors:  Xiang-Jia Song; Hong-Xia Ren; Min Xiang; Chen-Yi Li; Ying Zou; Xia Li; Zhi-Cheng Huang; Fang Tian; Li-Xin Wang
Journal:  J Org Chem       Date:  2020-06-25       Impact factor: 4.354

5.  Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.

Authors:  Shousong Cao; Farukh A Durrani; Youcef M Rustum
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

6.  Simultaneous targeting of COX-2 and AKT using selenocoxib-1-GSH to inhibit melanoma.

Authors:  Raghavendra Gowda; Subbarao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2012-10-30       Impact factor: 6.261

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 8.  The innovative potential of selenium-containing agents for fighting cancer and viral infections.

Authors:  Wesam Ali; Rosaria Benedetti; Jadwiga Handzlik; Clemens Zwergel; Cecilia Battistelli
Journal:  Drug Discov Today       Date:  2020-10-23       Impact factor: 7.851

9.  The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.

Authors:  Joshua E Allen; Jean-Nicolas Gallant; David T Dicker; Shantu Amin; Rosalyn B Irby; Arun K Sharma; Wafik S El-Deiry
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

10.  Novel method for rapid toxicity screening of magnetic nanoparticles.

Authors:  A Erofeev; P Gorelkin; A Garanina; A Alova; M Efremova; N Vorobyeva; C Edwards; Y Korchev; A Majouga
Journal:  Sci Rep       Date:  2018-05-10       Impact factor: 4.379

View more
  1 in total

1.  Synthesis and Biological Evaluation of S-, O- and Se-Containing Dispirooxindoles.

Authors:  Maksim Kukushkin; Vladimir Novotortsev; Vadim Filatov; Yan Ivanenkov; Dmitry Skvortsov; Mark Veselov; Radik Shafikov; Anna Moiseeva; Nikolay Zyk; Alexander Majouga; Elena Beloglazkina
Journal:  Molecules       Date:  2021-12-16       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.